Retrospective multicenter comparative study of the efficacy and safety between R-DHAC and R-DHAOx in diffuse large B-cell lymphoma or transformed follicular or marginal zone B lymphoma into aggressive lymphoma, as a second-line treatment.

MLA

Fouillet, Ludovic, et al. “Retrospective Multicenter Comparative Study of the Efficacy and Safety between R-DHAC and R-DHAOx in Diffuse Large B-Cell Lymphoma or Transformed Follicular or Marginal Zone B Lymphoma into Aggressive Lymphoma, as a Second-Line Treatment.” Leukemia & Lymphoma, vol. 65, no. 2, Feb. 2024, pp. 270–74. EBSCOhost, https://doi.org/10.1080/10428194.2023.2281270.

APA

Fouillet, L., Daguenet, E., Tavernier, E., Ghesquières, H., Bachy, E., Sesques, P., Tournilhac, O., Bay, J.-O., Michallet, A.-S., Sapet, M., Chalayer, E., Guyotat, D., Tinquaut, F., & Cornillon, J. (2024). Retrospective multicenter comparative study of the efficacy and safety between R-DHAC and R-DHAOx in diffuse large B-cell lymphoma or transformed follicular or marginal zone B lymphoma into aggressive lymphoma, as a second-line treatment. Leukemia & Lymphoma, 65(2), 270–274. https://doi.org/10.1080/10428194.2023.2281270

Chicago

Fouillet, Ludovic, Elisabeth Daguenet, Emmanuelle Tavernier, Hervé Ghesquières, Emmanuel Bachy, Pierre Sesques, Olivier Tournilhac, et al. 2024. “Retrospective Multicenter Comparative Study of the Efficacy and Safety between R-DHAC and R-DHAOx in Diffuse Large B-Cell Lymphoma or Transformed Follicular or Marginal Zone B Lymphoma into Aggressive Lymphoma, as a Second-Line Treatment.” Leukemia & Lymphoma 65 (2): 270–74. doi:10.1080/10428194.2023.2281270.